NasdaqCM - Delayed Quote • USD
Regulus Therapeutics Inc. (RGLS)
At close: April 18 at 4:00 PM EDT
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Joseph P. Hagan M.B.A. | CEO & Director | 920.73k | -- | 1969 |
| Ms. Crispina Calsada CPA | Chief Financial Officer | 500.87k | -- | 1970 |
| Mr. Christopher Ray Aker J.D. | Senior VP, General Counsel & Corporate Secretary | 524.79k | -- | 1961 |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director | -- | -- | 1969 |
| Mr. Daniel J. Penksa | VP of Finance & Controller | -- | -- | 1986 |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations | -- | -- | -- |
| Dr. Rekha Garg M.D., M.S. | Senior Vice President of Clinical Development & Regulatory | -- | -- | -- |
| Mr. Edmund Lee Ph.D. | Vice President of Translational Medicine | -- | -- | -- |
Regulus Therapeutics Inc.
4224 Campus Point Court
Suite 210
San Diego, CA 92121
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 30
Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Corporate Governance
Regulus Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 09, 2024S-3: Offering RegistrationsSee Full Filing
- Mar 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 18, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
- Jan 12, 2024S-8: Offering RegistrationsSee Full Filing
Upcoming Events
May 09, 2024 - May 13, 2024
Regulus Therapeutics Inc. Earnings Call
Related Tickers
LIXT Lixte Biotechnology Holdings, Inc.
3.3510
+0.63%
PEPG PepGen Inc.
11.85
+3.00%
CERO CERo Therapeutics Holdings, Inc.
1.5400
-9.41%
CLRB Cellectar Biosciences, Inc.
3.0400
-5.30%
ELEV Elevation Oncology, Inc.
4.0100
-3.14%
IMRN Immuron Limited
2.4500
+1.66%
XLO Xilio Therapeutics, Inc.
1.2800
+4.07%
NKGN NKGen Biotech, Inc.
0.8600
-16.50%
EQ Equillium, Inc.
1.7300
-3.35%
TRVI Trevi Therapeutics, Inc.
2.6850
+4.07%